Zhittya Genesis Medicine

09/01/2026

We just posted a new video! Watch it here: Ask the Trial Team

From complex mixtures to purified protein.The Fast Protein Liquid...

08/31/2026

From complex mixtures to purified protein.

The Fast Protein Liquid Chromatography (FPLC) system is a critical tool in protein purification, allowing researchers to separate and isolate specific proteins from complex biological mixtures.

Through a series of carefully formulated buffer washes, unwanted components are removed while the target protein is progressively purified. Multiple purification runs can be performed to obtain the high-purity protein required for downstream research and analysis.
At Zhittya, advanced protein purification is a crucial component in translating laboratory research into potential therapeutic applications.

🔬 Precision at the molecular level.

08/28/2026

Reliable outcomes start with reliable data. Every data point matters, and every step in the process contributes to better patient care. At Zhittya Genesis Medicine, we believe that consistency behind the scenes is what makes meaningful clinical insights possible.

08/26/2026

What if the body already has some of the tools it needs to repair itself?

At Zhittya Genesis Medicine, we’re studying FGF-1, a naturally occurring protein involved in processes such as blood vessel growth and tissue repair.

Through FDA-authorized clinical research, we’re exploring the potential of FGF-1 for patients facing serious circulatory and neurological conditions.

For patients with limited treatment options, research can represent something powerful: a reason to keep searching for answers.

Hope grounded in science. Questions driven by research. Possibilities worth exploring.

Learn more about the science and the patients behind the research. Link in bio.

08/24/2026

Meet the man behind the mission: Dan Montano, Chief Executive Officer of Zhittya Genesis Medicine.

Before biotech, Dan spent his career on Wall Street as an investment banker, leading the IPOs of more than 100 companies. In 1998, he made a different choice, stepping away from that world to devote himself fully to biotechnology.

That decision became the foundation of everything Zhittya is today. For over two decades, Dan has guided our mission: using FGF-1 to restore blood flow and give the body's own repair systems a chance to work, across Parkinson's, diabetes, chronic wounds, and more.

Today, we're celebrating Dan and the vision that started it all.

08/23/2026

Your body has a built-in repair system. What if we could help it work harder? 🧬

At Zhittya Genesis Medicine, we’re studying FGF-1 (Fibroblast Growth Factor 1) in FDA-authorized clinical trials, exploring its potential to help patients facing serious circulatory and neurological conditions.

This isn’t speculation, it’s science, and it’s giving patients real hope.

Learn more about the research and the patients behind it at
🔗 zgm.care (http://zgm.care/)
📖 Patient stories: pd-stories.com (http://pd-stories.com/)

08/22/2026

Microvascular disease is at the heart of many of the complications associated with Type-2 Diabetes. When the body's smallest blood vessels are damaged, tissues and organs receive less of the oxygen and nutrients they need, setting the stage for complications that can affect vision, kidney function, nerve health, wound healing, and cardiovascular wellness.

Understanding why microvascular health matters is an important step toward improving long-term outcomes. At Zhittya Genesis Medicine, we're committed to advancing approaches that prioritize vascular health as part of a comprehensive strategy for diabetes care.

Learn more about our mission and innovative approach to diabetes care by visiting our website.

zgm.care (http://zgm.care/)

08/20/2026

Al has been part of our FGF-1 research for six months. His brain imaging revealed a 21% increase in blood flow to the dopamine-producing region of the brain, and his family is seeing this reflected in his daily life.

"He was jumping into conversations, something he hasn't done in 10 years. His thoughts were so articulate and clear," his family shared. "We are celebrating you... Thank you for making such a difference in our lives."

Moments like this are why we do this work.

This is one story among the 250+ patients in our ongoing FGF-1 research. Read more anonymized patient experiences at pd-stories.com (http://pd-stories.com/).

These are individual experiences shared during an ongoing medical research study and are not a guarantee of results. FGF-1 is investigational.

08/16/2026

Chronic pain begins at the cellular level, which is why understanding its underlying mechanisms is key to developing more effective therapies. As research continues to uncover the role of mitochondrial health in neuropathic pain, new possibilities are emerging for addressing pain at its source, not just managing its symptoms.

FGF-1 is helping reshape this conversation. By supporting mitochondrial function and cellular homeostasis, it represents a promising, multi-mechanistic approach that targets several biological pathways involved in chronic pain. This evolving science has the potential to change how we think about pain management and improve outcomes for patients.

At Zhittya Genesis Medicine, we're committed to advancing innovative, science-driven therapies that explore the root causes of disease and expand what's possible in regenerative medicine.

08/14/2026

85 patients treated in our Type 2 diabetes program to date.

Every one of them volunteered to help answer a question that hasn't been answered before: can restoring microvascular circulation change the trajectory of metabolic disease?

We're grateful to every participant and every investigator who made that number possible, and we're just getting started.